The Jackson Laboratory

2017 Presenters

arrow

close
info:
Featured Speaker: Francis Collins, M.D., Ph.D.
arrow

Featured Speaker: Francis Collins, M.D., Ph.D.

Director, National Institutes of Health
close
info:
Content
Featured Speaker: Sandra Fenwick
arrow

Featured Speaker: Sandra Fenwick

President and CEO, Boston Children’s Hospital
close
info:
As President and Chief Executive Officer of Boston Children's Hospital, Sandra L. Fenwick leads the nation's foremost independent pediatric hospital and the world's leading center of pediatric medical and health research. Ms. Fenwick has been a driving force to improve the effectiveness and efficacy of the care provided at Boston Children’s while at the same time reducing the costs of care. Through a combination of hospital affiliations, outpatient specialty care centers, community health centers and regional partnerships, she has helped create a children’s health network providing high quality pediatric care in local settings. She has also expanded its commitment to and investment in both basic, translational and clinical research, care innovation and as well as prevention efforts focused on asthma, obesity, mental health and violence.Ms. Fenwick joined Boston Children’s in June of 1999 as senior vice president for Business Development, Strategy and Ambulatory Care Operations. In November of 1999, she was appointed Chief Operating Officer, was named President in October 2008 and was appointed President and Chief Executive Officer in October 2013. Boston Children’s is a 415-bed Harvard teaching hospital with over $2.2billion of revenues including $330M of research funding. Boston Children’s has 1,600 physicians, trains over 1,000 residents and fellows annually and more than 10,000 employees. She currently serves on the Board of Directors of CRICO, Ltd.(Cayman), Wyss Institute, Children’s Hospital Association, Children’s Hospitals Solutions for Patient Safety, Greater Boston Chamber of Commerce, MASCO, Inc, Jobs for Massachusetts, Inc., Massachusetts Digital Health Council and Boston Children’s Hospital. She is also a member of the Massachusetts Women’s Forum and Women Corporate Directors/Boston.Prior to her arrival at Boston Children’s, Ms. Fenwick served as senior vice president of System Development for CareGroup, Inc. From 1976 to 1996, she served in a number of roles at the Beth Israel Hospital including vice president and deputy director, vice president of Clinical Services Planning and Development, and vice president of Network Development for Beth Israel HealthCare. She holds a Bachelor’s degree from Simmons College with distinction and a Masters in Public Health degree in Health Services Administration from the University of Texas School of Public Health. She has received numerous awards and honorary degrees for her contribution to healthcare.
arrow

close
info:
Content
Edward Abrahams, Ph.D.
arrow

Edward Abrahams, Ph.D.

President, Personalized Medicine Coalition
close
info:
Edward Abrahams, Ph.D., is the president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.Previously, Dr. Abrahams was the executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been assistant vice president for federal relations at the University of Pennsylvania and held a senior administrative position at Brown University.Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.
Mark Adams. Ph.D.
arrow

Mark Adams. Ph.D.

Professor and Campus Director, J. Craig Venter Institute
close
info:
Dr. Mark Adams is Professor and Campus Director for the J. Craig Venter Institute in La Jolla, California. Dr. Adams comes from a rich background including industry, government, academic, and nonprofit settings. Dr. Adams was one of the founding scientists of The Institute for Genomic Research and of Celera Genomics, where he directed the large-scale sequencing and genome annotation groups. At JCVI he leads the bacterial genomics programs with a particular emphasis on evolutionary approaches to understanding the spread of multidrug-resistant bacteria.
Lisa Alderson
arrow

Lisa Alderson

President and CEO, Genome Medical
close
info:
Lisa Alderson is President and CEO of Genome Medical, a specialty medical practice and genomic services network delivering genome-centered patient care and physician education services. Previously she was co-founder and partner of Tech Care Now and chief commercial officer and strategy officer for Invitae. She received her MBA from Harvard Business School.
Lauren Ambrogio
arrow

Lauren Ambrogio

Chief Operating Officer, AOBiome
close
info:
Lauren Ambrogio joined the team in May of 2016, overseeing AOBiome's Research and Operational efforts. Prior to AOBiome, she was Chief Operating Officer at Q-State Biosciences where she provided leadership and oversight for a successful, fast-growing biotechnology start-up. In addition to her most recent roles, Ms. Ambrogio has held several management positions over the last 10 years merging her love for cutting-edge science and technology with operational excellence, including roles at the Dana Farber Cancer Institute, the Broad Institute, and Claritas Genomics. She brings expertise in genomics, project and portfolio management, product development, and corporate operations to the AOBiome team. Ms. Ambrogio is an author on numerous scientific papers, holds a BS in Molecular Genetics from the University of Rochester, and is a Certified Project Management Professional.
Nir Barzilai, M.D.
arrow

Nir Barzilai, M.D.

Professor and Ingeborg and Ira Leon Rennert Chair in Aging Research Director, Institute for Aging Research
close
info:
Dr. Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine and the director of the Glenn Center for the Biology of Human Aging and of the Nathan Shock Center of excellence in biology of aging. He is the Ingeborg and Ira Leon Rennert professor of Aging Research, professor of Medicine and Molecular Genetics and a member of the Diabetes Research Center, the Divisions of Endocrinology and Geriatrics. Dr. Barzilai’s interests focus on several basic mechanisms in the biology of aging, including the biological effects of nutrients on extending life and the genetic determinants of life span. He is an advisor to the National Institutes of Health on several projects and initiatives and study sections (currently on NIA-Biology). Dr. Barzilai is in the board of the American Federation for Aging Research, is its co-scientific director, and has served on several NIA study section. He is also a founder of CohBar Inc., a biotech that develops mitochondrial derived peptides as therapy for aging and its diseases. Dr. Barzilai was a recipient of numerous prestigious awards, including the Beeson Fellow for Aging Research, the Senior Ellison Foundation award, the Paul Glenn Foundation award and the NIA-Nathan Shock Award and the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research Award and the 2013 Rifkin lectureship. Dr. Barzilai is Israeli born and served as a medic and a physician in the IDF. He graduated from the Faculty of Medicine at the Technion, and completed his residency in Internal medicine at Hadassah Hospital in Jerusalem. He was an invited speaker to the 4th Israeli President Conference (2012) and a Vatican conference on Stem Cells and Aging (2013).
Morris Birnbaum, M.D., Ph.D.
arrow

Morris Birnbaum, M.D., Ph.D.

Senior Vice President and Chief Scientific Officer, Cardiovascular and Metabolic Disease Research Unit, Pfizer
close
info:
Morris J. Birnbaum, M.D., Ph.D. is Senior Vice President and Chief Scientific Officer of the Cardiovascular and Metabolic Disease (CVMED) Research Unit at Pfizer, which focuses on developing therapies to treat, slow or prevent disease progression and improve the quality of life of patients with obesity, type 2 diabetes (T2D), cardiovascular (CV) and kidney diseases. Dr. Birnbaum is a leading researcher in the signals that regulate and integrate metabolic pathways in liver, muscle and adipose tissue, and how they are disrupted in insulin resistant states.Dr. Birnbaum completed his undergraduate, graduate and medical training at Brown University in Providence, R.I. before moving to San Francisco for postdoctoral studies at the University of California. Following an associate professorship at Harvard Medical School, he went to the University of Pennsylvania as professor of Medicine. Dr. Birnbaum is currently the associate dean for Biomedical Cores and associate director of the Institute for Diabetes, Obesity and Metabolism. He was elected to membership in the Association of American Physicians in 2003 and made a fellow of the AAAS in 2007.
Stephen Bloch,
arrow

Stephen Bloch,

Partner, Canaan Partners
close
info:
A former entrepreneur and practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by the complexity in healthcare, whether regulatory, scientific or technical, Steve's mission at Canaan is to find companies that make healthcare delivery more efficient. Steve currently serves on the boards of companies in Digital Health (Truveris, DICOM Grid); BioPharma (Envisia, Liquidia, LQ3 and Marinus Pharmaceuticals (NASDAQ: MRNS)); Medical Devices (Mitraspan); and Diagnostics (Sample6). Before joining Canaan in 2002, Steve founded multiple start-ups, including Radiology Management Sciences (RMS), a pioneer in managing radiology benefits for health plans, where he was CEO for 6 years. Steve also helped start OmniSonics Medical Technologies, which engineered novel ultrasonic catheters for treating vascular occlusive disease, and he co-founded TeleRad, an early teleradiology services company. Prior to embarking on startups, Steve was a strategic consultant for the Arthur D. Little firm. Steve was a Ewing Marion Kauffman Fellow, an educational program to develop future leaders in venture capital.Steve obtained his AB from Dartmouth College, his MA in the history of science and public policy from Harvard, and his medical degree from the University of Rochester. Steve trained in medicine at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).
Ken Blount, Ph.D.
arrow

Ken Blount, Ph.D.

Head of External Research, Rebiotix
close
info:
Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes microbiome and small-molecule drug development, translational medical oncology, and RNA-targeting therapeutics. Dr. Blount is the Head of External Research at Rebiotix, where he is cultivating a portfolio of novel microbiome therapeutic programs. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections.Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Mark S. Blumenkranz, M.D., MMS
arrow

Mark S. Blumenkranz, M.D., MMS

HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University
close
info:
Mark S. Blumenkranz, M.D., MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University. He received his Undergraduate, Masters degree in biochemical pharmacology, and MD at Brown, Ophthalmic residency training at Stanford, and a Fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute. He was appointed to serve as the Department Chairman at Stanford from 1997 until 2015. He played a leading role in the planning, fundraising and construction of the Byers Eye Institute at Stanford and served as inaugural Director beginning with its opening in September 2010 through June 2015.He is an internationally known vitreo-retinal specialist, with notable contributions in the area of new laser systems, novel pharmaceuticals for macular diseases, ocular gene therapy and ophthalmic tele-health and technology development. He has served on the Editorial Boards of The American Journal of Ophthalmology, Retina, Ophthalmology, and Graefe¹s Archives for Ophthalmology. He is a past President of the American University Professors of Ophthalmology (AUPO), and a past President of the Retina Society and the Macula Society. He is a member of the Steering Committee of the Audacious Goals Initiative of the NEI, and is a Fellow of the Corporation of Brown University, where he is the Chair of the Medical School Committee. He is the recipient of multiple honors and awards in the field. These include the American Academy of Ophthalmology Lifetime Achievement Award and Edward Jackson Lecture, the Heed Award, The Schepens Medal, the Pyron Award, the Wacker Prize, the Gass Award and the OIS Lifetime Innovator Award.Dr. Blumenkranz has a longstanding interest and expertise in university corporate technology transfer and early stage biomedical company and is the author of more than 150 peer reviewed articles and 18 patents. He was a director of Oculex Pharmaceuticals, a privately held pharmaceutical company that pioneered the use of bio-erodable polymers for extended release of ocular steroids. At Oculex he was also Chairman of the SAB and the principal designer of the successful phase 2 Ozurdex trial, leading to its acquisition by Allergan in 2003. He served as a co-founder, Director and Chairman of the SAB of Macusight, an ophthalmic pharmaceutical company developing proprietary mTor inhibitors for ophthalmic disease, which was acquired by Santen in 2010. He was a founder and director of Peak Surgical, an innovator in pulsed plasma mediated electro-surgery that was acquired by Medtronics in 2011. In 2004 he co-founded Optimedica Corporation for which he co-wrote the foundation IP for the PASCAL and Catalys lasers, and which was acquired by AMO in 2013. In 2006 co-founded Adverum Biotechnologies (ADVM; NASDAQ) a gene therapy company and served as Chairman of the Board until 2016. He was a co-founder and director of Oculeve, a dry eye company employing a neuro-modulatory approach to therapy, which was acquired by Allergan in August of 2015. He is a co-founder and serves as a director of Digisight Corporation a venture financed ophthalmic digital health company. He is a co-founder and the managing partner of Lagunita Biosciences LLC an early stage biotechnology and medtech investment company.
Ted Borgstadt
arrow

Ted Borgstadt

CEO, TrestleTree
close
info:
Ted R. Borgstadt is the CEO and co-founder of TrestleTree, LLC, a health transformation company that was founded on the belief that anyone, regardless of level of motivation or lack of adherence, can change life-impacting health behaviors and sustain those changes long-term. TrestleTree gives employees and their families the opportunity to make lasting behavior change and improve their health in ways they may not have been able to achieve previously. With TrestleTree, Ted has invested the past 16 years focused on the health, safety and wellbeing of the individual, the family, the workplace and the community. In January 2015 TrestleTree, LLC was acquired and is now a Harvard Pilgrim Health Care Family Company. Prior to starting TrestleTree, Ted owned retail pharmacies in Northwest Arkansas. Ted is a graduate of Evangel University, Springfield, MO. He is also a founding board member of LifeSource International, a Fayetteville, Arkansas non-profit organization with a holistic approach to providing physical, mental, emotional and spiritual support to families.
Nancy Cox, Ph.D.
arrow

Nancy Cox, Ph.D.

Director, Vanderbilt Genetics Institute; Director, Division of Genetic Medicine; Mary Phillips Edmonds Gray Professor of Genetics
close
info:
Dr. Nancy Cox is a quantitative human geneticist with a long-standing research program in identifying and characterizing the genetic component to common human diseases; current research is focused on large-scale integration of genomic with other “-omics” data as well as biobank and electronic medical records data.
Anthony Elias, M.D.
arrow

Anthony Elias, M.D.

Professor of Medicine, University of Denver, Colorado
close
info:
Dr. Elias' focus is on experimental therapeutics for breast cancer (BC), describing molecular changes associated with anti-estrogen and/or chemotherapy drug resistance using collaborations with a number of research laboratories, and tissue banking. Another interest is experimental therapy for sarcomas. Dr. Elias is focused on clinical breast cancer research and is the director of the clinical breast oncology program. This comprehensive program includes a weekly multi-disciplinary clinic and tumor board, a hereditary clinic, benign breast complaint clinic, a screening and breast imaging program, in addition to daily breast specialty oncology clinics. The sarcoma program includes consult/new patient clinics as well as follow-ups. Dr. Elias is the principal investigator on numerous national and local therapeutic trials and is institution PI for the SWOG grant. He is a member of the SWOG breast committee. He is also the Associate Director of the Cancer Center for clinical sciences and oversees the Clinical Investigations Core. He received his M.D. from New York University School of Medicine.
Anthony B. Evnin, Ph.D.
arrow

Anthony B. Evnin, Ph.D.

Partner, Venrock
close
info:
Dr. Evnin is a partner at Venrock, a venture capital firm, and on the Board of Directors of AVEO Pharmaceuticals, Infinity Pharmaceuticals, Juno Therapeutics and Constellation Pharmaceuticals and formerly a director of over 35 other biotech companies. He is a trustee of The Jackson Laboratory; member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center and of the Board of Directors of the Albert and Mary Lasker Foundation; director of the New York Genome Center; and Trustee Emeritus of The Rockefeller University and of Princeton University. He received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Andrew A.F. Hack, M.D., Ph.D.
arrow

Andrew A.F. Hack, M.D., Ph.D.

Chief Financial Officer, Editas Medicine
close
info:
Andrew A. F. Hack, M.D., Ph.D., has served as Chief Financial Officer of Editas Medicine since July 2015. Prior to joining Editas, from May 2011 to June 2015, Dr. Hack was a portfolio manager at Millennium Management LLC, an institutional asset manager, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium Management, Dr. Hack was a healthcare analyst at HealthCor Management, L.P., a registered investment advisor, from December 2008 to May 2011. Prior to HealthCor, Dr. Hack served as a healthcare analyst for hedge fund Carlyle-Blue Wave Partners and as principal of the MPM BioEquities Fund, a hedge fund that was affiliated with MPM Capital. Dr. Hack began his investment career covering the biotechnology sector at investment banks Banc of America Securities LLC and Rodman & Renshaw, LLC. Dr. Hack co-founded Reify Corporation, a life science tools and drug discovery company. Dr. Hack serves as a director of Mersana Therapeutics, Inc., a private company. Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.
Julian Harris, M.D., M.B.A.
arrow

Julian Harris, M.D., M.B.A.

President, CareAllies
close
info:
Dr. Julian Harris is President of CareAllies, an innovative population health management services company focused on helping physician groups and delivery systems navigate the transition to value-based care.Julian joined Cigna in September 2015 to accelerate the company’s delivery of value-based products and solutions to customers and providers in local markets. He became President of CareAllies in June 2016.Prior to Cigna, Julian served as the Associate Director for Health in the White House Office of Management and Budget (OMB). As the federal government’s chief health care budget official, he oversaw $1 trillion in spending and policy for a range of coverage programs, including Medicare, Medicaid, Marketplaces, the Centers for Medicare & Medicaid Services (CMS) Innovation Center, and the Federal Employees Health Benefits Program. Julian led OMB’s engagement and oversight of agencies on initiatives as diverse as developing new CMS Medicare ACO and bundled payment models, streamlining the Meaningful Use rules, replacing Sustainable Growth Rate (SGR), and establishing the federal government’s 50/90 value-based payment goal.During his time as the chief executive of the $11 billion Medicaid program in Massachusetts, Julian led the development of a primary care-centered ACO program, built value-based payment into the country’s first Medicare-Medicaid duals demonstration, and launched the Delivery System Transformation Initiative to accelerate safety net hospitals’ transition to value-based payment.Julian has supported and led public and private sector delivery system reform and population health projects in the U.S. and abroad. He has also advised technology startups, physician groups, investors and delivery systems on innovative approaches to navigating and supporting the transition to value-based payment.Julian trained in internal medicine and primary care at Harvard Medical School’s Brigham & Women’s Hospital, and he worked as a hospitalist at Cambridge Health Alliance. He graduated with a Bachelor of Arts degree in Health Policy & Medical Ethics from Duke University, and he holds a Master of Science degree from Oxford University. He is also a graduate of the Health Care Management MBA Program at the Wharton School of Business and the School of Medicine at University of Pennsylvania.
George Kuchel, M.D.
arrow

George Kuchel, M.D.

Professor and Travelers Chair in Geriatrics and Gerontology/Director, UConn Center on Aging, UConn Health
close
info:
Dr. Kuchel is the director of the University of Connecticut Center on Aging, which brings together clinicians, educators, clinical investigators, basic scientists and researchers conducting health outcome/population studies - all committed to the discovery of strategies for promoting independence and health in old age. Dr Kuchel’s research is focused on Precision Gerontology, an approach designed to help older adults remain and healthy independent in a manner that is both individualized and guided by mechanisms. To that end, his work has emphasized potentially targetable pathways contributing to functional declines involving host defense, mobility, continence and cognition.
David Ledbetter, Ph.D, FACMG
arrow

David Ledbetter, Ph.D, FACMG

Executive Vice President and Chief Scientific Officer, Geisinger Health System
close
info:
Executive Vice President and Chief Scientific Officer at Geisinger Health System. He came to Geisinger from Atlanta’s Emory University School of Medicine where he was the Robert W. Woodruff Professor and Director of the Division of Medical Genetics in the Department of Human Genetics.
James Lu
arrow

James Lu

CO-FOUNDER & VP APPLIED GENOMICS, HELIX
close
info:
James is a co-founder and VP of Applied Genomics at Helix, a consumer genomics company that is empowering every person to discover insights into his or her own DNA through an ecosystem of high-quality content partners. Prior to Helix, James was an Associate in Research at Duke University where he focused on translational genomics and methodologies for extracting computational phenotypes from electronic medical records. James has also explored a broad range of research topics in population genetics and mendelian genomics. Earlier in his career James spent time at Merck & Co where he focused on manufacturing process optimization and Devon Park Bioventures, a Philadelphia based healthcare venture capital firm. James holds a B.S. and M.S. in Chemical Engineering from Stanford University. He also received a M.D. and Ph.D from Baylor College of Medicine.
Anita McGahan, Ph.D.
arrow

Anita McGahan, Ph.D.

Rotman Chair in Management, Professor of Strategic Management, University of Toronto
close
info:
Dr. McGahan is professor and Rotman chair in Management at the Rotman School of Management at the University of Toronto. She is cross appointed to the Munk School of Global Affairs and the Physiology Department of the Medical School; is senior associate at the Institute for Strategy and Competitiveness at Harvard University; is the chief economist in the Division of Health and Human Rights at the Massachusetts General Hospital; and is president of the Academy of Management. Dr. McGahan earned both her Ph.D. and A.M. at Harvard University. She holds an M.B.A. from Harvard Business School, and a BA from Northwestern University. She also spent several years at both McKinsey & Company and Morgan Stanley & Company and was previously on the faculties of both Harvard Business School and Boston University. Her credits include three books and over 100 articles, case studies, notes and other published material on competitive advantage, industry evolution, and financial performance. Her current research emphasizes entrepreneurship in the public interest and innovative collaboration between public and private organizations. In 2010, she was awarded the Academy of Management BPS Division’s Irwin Distinguished Educator Award and, in 2012, the Academy conferred on McGahan its Career Distinguished Educator Award. In 2012 she was elected a Fellow of the Strategic Management Society, and in 2015 she was elected a Fellow of the Academy of Management.
S. Jay Olshansky, Ph.D.
arrow

S. Jay Olshansky, Ph.D.

Professor, School of Public Health, Division of Epidemiology and Biostatistics, University of Illinois at Chicago/Co-Founder and Chief Scientist, Lapetus Solutions, Inc.
close
info:
Dr. Olshansky received his Ph.D. in Sociology at the University of Chicago in 1984. He is currently a Professor in the School of Public Health at the University of Illinois at Chicago, Research Associate at the Center on Aging at the University of Chicago and at the London School of Hygiene and Tropical Medicine, and Chief Scientist at Lapetus Solutions, Inc. The focus of his research to date has been on estimates of the upper limits to human longevity, exploring the health and public policy implications associated with individual and population aging, forecasts of the size, survival, and age structure of the population, pursuit of the scientific means to slow aging in people (The Longevity Dividend), and global implications of the re-emergence of infectious and parasitic diseases. Dr. Olshansky is on the Board of Directors of the American Federation of Aging Research; he is the first author of The Quest for Immortality: Science at the Frontiers of Aging (Norton, 2001) and A Measured Breath of Life (2013); and co-edited Aging: The Longevity Dividend (Cold Spring Harbor Laboratory Press, 2015). In 2016, Dr. Olshansky was honored with the Donald P. Kent Award from the Gerontological Society of America, the Irving S. Wright Award from the American Federation for Aging Research, and he was named one of Next Street’s Influencer in Aging.
Becky Parker, Ph.D.
arrow

Becky Parker, Ph.D.

Chief Training Officer, Trestletree LLC
close
info:
A Licensed Clinical Psychologist, Dr. Parker serves as the Chief Training Officer for TrestleTree, after serving as Director of Coach Operations and Senior VP of Operations. She received her M.A. and Ph.D. from the University of Arkansas, her B.S. from the University of Florida, and completed her post-doctoral fellowship at the VA Medical Center in Minneapolis, MN. As the Chief Training Officer, Dr. Parker oversees coaching operations and coaching personnel for TrestleTree, including the hiring, training and supervision of TrestleTree Health Coaches. She joined TrestleTree in 2006 and works closely with the CEO to lead the operational direction of the organization. Dr. Parker is a former recipient of an NIH National Research Service Award and has dedicated herself to the prevention and treatment of difficult health behaviors, with special attention given to the pragmatic and effective application of behavior change theories and processes.
David Sabow
arrow

David Sabow

Managing Director, Head of Life Science & Healthcare, Silicon Valley Bank
close
info:
David Sabow serves as the head of Silicon Valley Bank’s life science and healthcare practice, as well as the group head for the Bank’s client funds and products businesses. In this capacity David manages SVB’s life science and healthcare deal teams across the country, is responsible for the Bank’s on and off balance sheet deposit strategy and is the executive lead for the Bank’s products. David frequently presents at global industry conferences, has been a guest lecturer at Northeastern University’s Nanomedicine Graduate program, and has been published in Forbes for his insight on trends impacting China’s life science and healthcare market.Prior to joining Silicon Valley Bank, David spent almost nine years in the life science investment banking practice at Canaccord Genuity, where he participated in public financings and M&A transactions. While at Canaccord, David worked on both domestic and international transactions across the spectrum of life science and healthcare. Prior to joining Canaccord, David worked as a relationship manager with U.S. Bank. Outside of work David is the co-chair of the Kelly Brush Foundation’s Inspire!Boston event, and is a member of the Board of Advisors for Beth Israel Deaconess Hospital – Needham. David completed the executive program at Dartmouth’s Tuck School, focusing on Leadership and Strategic Impact. He graduated with distinction from Santa Clara University and lives in Needham, Massachusetts with his wife and three children.
Alan Sachs, M.D., Ph.D.
arrow

Alan Sachs, M.D., Ph.D.

Chief Scientific Officer, Thermo Fisher Scientific
close
info:
Alan Sachs is the Chief Scientific Officer for Thermo Fisher Scientific. He served as the Chief Scientific Officer for Life Technologies/Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge, MA. Dr. Sachs’ academic work focused on understanding of the role of the poly(A) tail in translation and mRNA stability. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, received his Ph.D. with Roger Kornberg in Cell Biology at Stanford Medical School, received his M.D. from Stanford Medical School, and completed a post-doctoral fellowship with Ron Davis in the Department of Biochemistry, Stanford Medical School.
Eric Schadt, Ph.D.
arrow

Eric Schadt, Ph.D.

Professor and Chair, Mount Sinai
close
info:
Dr. Schadt joined the Icahn School of Medicine in 2012, and also founded the Icahn Institute for Genomic and Multiscale Biology. Previously, he was the chief scientific officer at Pacific Biosciences. He was a founding member of Sage Bionetworks. Other prior positions included being executive director, Genetics for Rosetta Inpharmatics/Merck Research Labs. He received his Ph.D. in Biomathematics from the University of California, Los Angeles, and a Master’s degree in Pure Mathematics from the University of California, Davis. His Bachelor of Science degree in Mathematics and Computer Science is from Cal Poly.
Michael Snyder, Ph.D.
arrow

Michael Snyder, Ph.D.

Stanford W. Ascherman Professor and Chair, Department of Genetics and Director, Center for Genomics and Personalized Medicine, Stanford University
close
info:
Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.
C. Todd Staub
arrow

C. Todd Staub

Senior VP, Physician Relations, OptumCare
close
info:
Todd Staub is the Senior Vice President for Physician Relations at OptumCare - a division of Optum. In this role, Todd is helping to establish and strengthen relationships with externalmedical organizations, to bring new medical groups into the national OptumCare care delivery network, and to develop a research and education capability in OptumCare.Optum is working to transform the U.S. healthcare system into one that serves people with greater value. With access to the unprecedented array of capabilities and resources in Optum, OptumCare is creating a transcontinental delivery network with a strategy that is ambulatory,community-based and primary care-driven. Todd is working with others to support its physicianledgovernance structure, which accommodates regional variations in groups, while building acohesive, integrated entity over time.Todd serves on Board of Directors of the American Medical Group Association. He is working with AMGA leadership, board members, and staff to grow and strengthen the nation's leading organization for medical groups and health systems in the advancement of high performance health. As part of ProHealth Physicians and now OptumCare, Todd has been a member of AMGA for the last fifteen years.Todd is the immediate past Chairman of the Board for ProHealth Physicians, an integrated primary care group practice in Connecticut. ProHealth Physicians serves over 400,000 patients in 90 locations throughout the state. Todd was a founding board member of the group. Since its inception in 1997, ProHealth Physicians has been redesigning health care delivery around the basic principles of primary care – wellness, prevention, early detection, optimal intervention, and the coordination of care. The goal of these efforts is to improve the health status of people atlower cost, as individuals and as a population. In December 2015, ProHealth Physicians joined with OptumCare.Todd worked with others in ProHealth to found the Connecticut Center for Primary Care in 2002,a non‐ profit organization devoted to research and education on primary care issues and now serves as the Chair of Board of Directors. He also helped to create the Primary Care Coalition of Connecticut, which brings together the broad primary care community from diverse practice settings across the state and to establish the CCPC Annual Primary Care Summit - a statewide event for the greater primary care community and fundraiser for CCPC.
Roger Stein, Ph.D.
arrow

Roger Stein, Ph.D.

Research Affiliate, MIT Laboratory for Financial Engineering and Adjunct professor of Finance New York University, Stern School of Business.
close
info:
Dr. Stein has been actively engaged in developing, implementing and writing about new approaches to applied risk modeling and financial prediction for almost 30 years. He and his teams have developed, implemented and delivered products and services that have become industry benchmarks in banking and finance. He is currently adjunct professor of Finance at NYU’s Stern School of Business and research affiliate at the MIT Laboratory for Financial Engineering. He was perviously senior lecturer in Finance at the MIT Sloan School of Management and is an affiliated researcher at the Center for Risk Management Research, University of California, Berkeley. His current research interests are in the areas of systemic risk, credit risk, model risk and validation, biomedical funding, data science, FinTech and the interface between data mining and financial theory. In addition to his professional work he was the founder and president of the Consortium for Systemic Risk Analytics and a member of the Advisory Council of the Museum of Mathematics; on the Board of PlaNet Finance, USA, and on the Academic Advisory Board of the EC’s SYstemic Risk Tomography Project (SYRTO). Dr. Stein holds a Ph.D. and Master’s degree from the Stern School of Business, New York University, and a Bachelor’s degree in Mathematics and Japanese Studies from the State University of New York at Binghamton
David Steinberg
arrow

David Steinberg

Chief Innovation Officer, PureTech Health
close
info:
Mr. Steinberg is the chief innovation officer at PureTech Health. As a member of PureTech Health, he has served as founding CEO and board member of multiple programs, including Vedanta Biosciences, Entrega Biosciences, Vor Biopharma and Commense Health. He also served as chief business officer of Follica, Inc. and vice president of Operations for Satori Pharmaceuticals. Previously, he was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology clients. Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. He received his B.A. in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Booth School of Business with an M.B.A. in Strategy and Finance. Mr. Steinberg is also a member of the UChicago Tech Innovation Fund Advisory Committee.
Andrew Ury, M.D.
arrow

Andrew Ury, M.D.

Founder and Chairman/CEO, ActX
close
info: